Neuroendocrine and Metabolic Disorder Solutions
Changing the Face of Oral Absorption Drugs
OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.
Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:
- Liver Disease (NASH)
- Low Testosterone (Hypogonadism)
- Recurrent Pre-Term Birth
- Postpartum Depression
Press Releases
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a...
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for the year ended December 31, 2023 and...